Does Metformin Slow Aging? What the Evidence Shows

Metformin is cheap. It is generic, taken by millions, and has a decades-long safety record. It switches on an enzyme called AMPK, which cells use to sense low energy. In some model organisms it extends life. So if you were going to nominate an existing drug as a candidate for slowing human aging, it is a reasonable first pick. The field did exactly that.

What follows is not an argument that the idea is silly. It is an account of how much has actually been demonstrated in people. That is considerably less than the popular version suggests.

TAME stands for Targeting Aging with Metformin. It is the study you will see referenced in almost every article on this subject. It was announced around 2015. The design was to enrol roughly 3,000 people aged 65 to 79, and to test whether metformin delays the accumulation of age-related disease.

As of July 2026, checked three independent ways:

• There is no ClinicalTrials.gov registration for TAME. Every "TAME" result in the registry is an unrelated trial.
• It is not fully funded. The National Institute on Aging has put around $5 million towards it, but the investigators put the cost of running it at $45 million to $70 million. The trial, Barzilai told NPR in 2024, "can get underway when the money comes in."
• The American Federation for Aging Research is still fundraising to launch it. Its own page files TAME under "Need — Raising Funds to Launch". Among what is still required, it lists: "Visionary donors", "3,000 individuals... to participate", and "An 'indication' for aging".

Nir Barzilai is the trial's lead investigator. He put it plainly to STAT News in 2022: "I'm on the record saying I'm pretty sure it will start this year, for the last seven years. I have no credibility anymore. It's just incredibly frustrating. But it's going to happen, because it has to happen."

Speaking to NPR in 2024, he gave the reason: "The main obstacle with funding this study is that metformin is a generic drug, so no pharmaceutical company is standing to make money."

That is a real and depressing structural problem in medical research, and Barzilai is right to name it. But it does not change what a reader needs to know. TAME has enrolled nobody and reported nothing. Some pages suggest TAME is underway, or that it has produced results. Several AI-generated pages ranking for this topic do exactly that. It is simply wrong.

AMPK: real, but probably not the point

Metformin does activate AMPK. That much is not in dispute.

The complication is a 2010 experiment. Mice were engineered to lack AMPK in the liver. Metformin lowered their blood glucose perfectly well anyway. The researchers described themselves as surprised. Whatever AMPK is doing, it is not required for the drug's signature effect.

The scientist who discovered AMPK co-authored a 2017 review. It concluded that metformin acts through both AMPK-dependent and AMPK-independent mechanisms, and that "more work is required to truly understand how this drug works in its target population: individuals with type 2 diabetes."

So "it activates AMPK, therefore it slows aging" skips several steps. Those steps have not been established.

"Mimics caloric restriction" is a hypothesis

Researchers use this phrase as an analogy. Metformin produces some cellular signatures that resemble those of eating less. That is a reason to investigate, not a finding. It is regularly repeated as though it were settled, and it is not.

Human lifespan: no randomised evidence at all

This is the part that matters most, and gets stated least. There is no randomised trial showing metformin extends human lifespan or healthspan. Not a small one. Not a preliminary one. The question has not been answered, because the study designed to answer it has not run.

Observational studies have suggested benefits. One widely cited analysis reported that people with diabetes on metformin outlived people without diabetes. It did not survive closer examination. And it is vulnerable to exactly the immortal time bias that wrecked the metformin cancer literature.

Here is the finding that should give any enthusiast pause. It is randomised, which most of this field's evidence is not.

The MASTERS trial put 94 healthy older adults through 14 weeks of supervised progressive resistance training. They were randomised to metformin or placebo. The placebo group gained more lean body mass, and more thigh muscle mass. Scans confirmed greater increases in both muscle area and density on placebo. The authors' conclusion: "metformin negatively impacts the hypertrophic response to resistance training in healthy older individuals."

A companion analysis confirmed it, and Nir Barzilai himself co-authored that one: "We found that metformin blunted PRT-induced muscle hypertrophic response." This is not a hostile result produced by sceptics outside the field.

A separate randomised trial found that metformin inhibited mitochondrial adaptations to aerobic exercise training in older adults.

There is an irony worth sitting with. In MASTERS, metformin did increase AMPK signalling. That is the very mechanism the longevity case rests on. And the increase coincided with the blunted muscle gain.

Keeping muscle and fitness into later life is one of the few interventions with solid evidence behind it. A drug that measurably interferes with that, taken speculatively for an unproven benefit, is a trade worth understanding before you make it.

• Whether metformin extends human lifespan. No randomised data.
• Whether it protects against dementia. Genuinely unresolved.
• Whether people without diabetes benefit at all.

Not knowing is a legitimate answer. Here, it is the accurate one.

Metformin is a prescription drug. It carries a boxed warning about lactic acidosis, a dangerous build-up of acid in the blood. It has real contraindications, including reduced kidney function. And it has a well-documented association with vitamin B12 deficiency over time. It is not a supplement. Taking it speculatively is a medical decision.

If you have type 2 diabetes and are prescribed metformin, none of this is an argument to stop. This page is about the second claim layered on top: that it slows aging. It is about how much of that has actually been shown.

Every figure above comes from the trial publication or regulator named beside it. None comes from a summary of one. Where the honest answer is that nobody knows, this page says so rather than filling the gap.

Educational information, not medical advice. Do not start, stop or change any medication or supplement because of a web page — including this one. If you are on cancer treatment, tell your oncology team about everything you take, including supplements. Spotted an error? Please email corrections@cancerexplained.org or use /corrections.

• PubMed — Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: the MASTERS trial
• PubMed — Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults
• PubMed — The mechanisms of action of metformin
• NPR — Cheap longevity drug? Researchers aim to test if metformin can slow down aging (2024)
• DailyMed — Metformin hydrochloride tablet: boxed warning, contraindications and vitamin B12 monitoring